Lercanidipine information

Lercanidipine
Clinical data
Trade names	Zanidip, Leridip
AHFS/Drugs.com	UK Drug Information
Pregnancy; category	C (no data in humans);
Routes of; administration	Oral
ATC code	C08CA13 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	~10% (due to first-pass effect)
Protein binding	>98%
Metabolism	Mainly CYP3A4
Elimination half-life	8–10 hours
Duration of action	≥ 24 hours
Excretion	Urine (50%)
Identifiers
	IUPAC name (RS)-2[(3,3-Diphenylpropyl)(methyl)amino]-1,1-dimethylethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;
CAS Number	100427-26-7 ; 132866-11-6 (HCl);
PubChem CID	65866;
DrugBank	DB00528 ;
ChemSpider	59276 ;
UNII	V7XTJ4R0BH;
KEGG	D08111 ;
ChEMBL	ChEMBL250270 ;
CompTox Dashboard (EPA)	DTXSID2048327 ;
ECHA InfoCard	100.235.079
Chemical and physical data
Formula	C36H41N3O6
Molar mass	611.739 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [O-][N+](=O)c1cccc(c1)C4C(=C(/N\C(=C4\C(=O)OC(C)(C)CN(CCC(c2ccccc2)c3ccccc3)C)C)C)\C(=O)OC;
	InChI InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3 ; Key:ZDXUKAKRHYTAKV-UHFFFAOYSA-N ;
	(verify)

Lercanidipine (trade name Zanidip, among others) is an antihypertensive (blood pressure lowering) drug. It belongs to the dihydropyridine class of calcium channel blockers, which work by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. This lowers the blood pressure and allows the heart to work more efficiently.^[1]

The drug acts more slowly than older dihydropyridines.^{[citation needed]} It probably has fewer adverse effects, but a comparatively high potential for drug interactions.

It was patented in 1984 and first approved for medical use in 1997.^[2] The US FDA refused to approve the drug, and lercanidipine is not marketed in USA.^[3]

^ Barrios V, Escobar C, Navarro A, Barrios L, Navarro-Cid J, Calderón A (November 2006). "Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study". International Journal of Clinical Practice. 60 (11): 1364–1370. doi:10.1111/j.1742-1241.2006.01176.x. PMC 1636683. PMID 17073834.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 466. ISBN 9783527607495.
^ "NCATS Inxight Drugs — LERCANIDIPINE HYDROCHLORIDE". drugs.ncats.io. Retrieved 2024-04-16.

[1] Barrios V, Escobar C, Navarro A, Barrios L, Navarro-Cid J, Calderón A (November 2006). "Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study". International Journal of Clinical Practice. 60 (11): 1364–1370. doi:10.1111/j.1742-1241.2006.01176.x. PMC 1636683. PMID 17073834.

[2] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 466. ISBN 9783527607495.

[3] "NCATS Inxight Drugs — LERCANIDIPINE HYDROCHLORIDE". drugs.ncats.io. Retrieved 2024-04-16.

Lercanidipine information

and 28 Related for: Lercanidipine information

Lercanidipine

ATC code C09

Ketamine

Calcium channel blocker toxicity

Cocaine

Benzocaine

Topiramate

Thiazide

ATC code C08

Gabapentin

Calcium channel blocker

Promethazine

Chlorphenamine

Dihydropyridine calcium channel blockers

Cholesterol

Kava

Pregabalin

Schedule H

List of cardiac pharmaceutical agents

Phenibut

Lorazepam

Meclizine

Lidocaine

Triamterene

Diphenhydramine

Baclofen

Amlodipine

Domperidone